Corticosteroid osteoporosis Kortikoidosteoporose

Journal/Book: Z Rheumatol 2000; 59: I/45-47. 2000;

Abstract: P.N. Sambrook Sydney University Dept. of Rheumatology Royal North Shore Hospital Sydney Australia E-mail: [email protected] Summary Corticosteroids are widely used in the treatment of patients with chronic inflammatory diseases. Since the most rapid bone loss occurs in the first 12-24 months after commencing high dose corticosteroids it is important to consider two different therapeutic situations (a) prevention in patients starting corticosteroids and (b) treatment of patients on chronic corticosteroids who will already have some significant degree of corticosteroid related bone loss. An adequate calcium intake is recommended and any contributing factors to osteoporosis should be treated. A bone density will give information about the future risk of osteoporotic fracture and the need for active pharmacological treatment. Patients commencing high dose long-term corticosteroid therapy should be treated prophylactically with a bisphosphonate and/or active vitamin D metabolites (alphacalcidol or calcitriol) and the treatment may need to be continued for 1-2 years. Patients on chronic corticosteroids may improve their bone density by treatment with bisphosphonates and vitamin D metabolites (including the calciferols). In postmenopausal women concomitant use of estrogen replacement therapy is also appropriate. It is important in a patient on long-term therapy to review the need for continuing treatment or the possibility of dosage reduction. Schm

Keyword(s): Bone - fracture - corticosteroids

Zurück | Weiter